Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists

Respiratory Medicine

Volumn 100, Issue 4, 2006, Pages 595-609

  Mapel, Douglas W ^a,b   Hurley, Judith S ^b   Roblin, Douglas ^c   Roberts, Melissa ^b   Davis, Kourtney J ^d   Schreiner, Robert ^c   Frost, Floyd J ^b  

^a LOVELACE CLINIC FOUNDATION   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c KAISER PERMANENTE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Bronchodilators; Chronic obstructive pulmonary disease; Corticosteroids; Gender; Survival

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; THEOPHYLLINE;

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REACTION TIME; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SURVIVAL ANALYSIS;

EID: 33344465992     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.08.006     Document Type: Article

References (64)

1. The GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of COPD, 2004 Update. Accessed at www.GOLDCOPD.com, December 1, 2004.
2. B.R. Celli W. MacNee A. Agusti et. al. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur Respir 23 2004 932-946
3. M. Saetta G. Turato P. Maestrelli C.E. Mapp L.M. Fabbri Cellular and structural bases of chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1304-1309
4. P.M. O'Byrne D.S. Postma The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease Am J Respir Crit Care Med 159 1999 S41-S63
5. P.M.A. Calverley Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 341-342
6. P.J. Barnes Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 342-344
7. D.S. Postma H.A.M. Kersjens Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 160 1999 S66-S71
8. D.D. Sin P. Lacy E. York S.F. Man Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease Am J Respir Crit Care Med 170 2004 760-765
9. K.L. Hattotuwa M.J. Gizycki T.W. Ansari P.K. Jeffery N.C. Barnes The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. A double-blind, placebo-controlled biopsy study Am J Respir Crit Care Med 165 2002 1592-1596
10. B. Balbi M. Majori S. Bertacco et. al. Inhaled corticosteroids in stable COPD patients-do they have effects on cells and molecular mediators of airway inflammation? Chest 117 2000 1633-1637
11. M. Confalonieri E. Mainardi R. Della Porta et. al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease Thorax 53 1998 583-585
12. C.G. Llewellyn-Jones T.A.J. Harris R.A. Stockley Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema Am J Respir Crit Care Med 153 1996 616-621
13. A.B. Thompson M.B. Mueller A.J. Heires et. al. Aerosolized beclomethasone in chronic bronchitis: Improved pulmonary function and diminished airway inflammation Am Rev Respir Dis 146 1992 389-395
14. S.V. Culpitt W. Maziak S. Loukidis J.A. Nightingale J.L. Matthews P.J. Barnes Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 1999 1635-1639
15. V.A. Keatings A. Jatakanon Y.M. Worsdell P.J. Barnes Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD Am J Respir Crit Care Med 155 1997 542-548
16. P.L. Paggiaro R. Dahle I. Bakran L. Frith K. Hollingworth J. Efthimiou Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group Lancet 351 1998 773-780
17. N.A. Jarad J.A. Wedzicha P.S. Burge P.M.A. Calverley An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease Respir Med 93 1999 161-168
18. P.S. Burge P.M. Calverley P.W. Jones S. Spencer J.A. Anderson T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial BMJ 320 2000 1297-1303
19. A. Alsaeedi D.D. Sin F.A. McAlister The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials Am J Med 113 2002 59-65
20. S. Spencer P.M. Calverley P. Sherwood Berge et. al. Health status deterioration in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 122-128
21. P. Van der Valk E. Monninkhof J. Van der Palen G. Zielhuis C. Van Herwaarden Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 2002 1358-1363
22. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902-1909
23. D.A. Mahler P. Wire D. Horstman et. al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 2002 1084-1091
24. P. Calverley R. Pauwels J. Vestbo et. al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial Lancet 361 2003 449-456
25. W. Szafranski A. Cukier A. Ramirez et. al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74-81
26. N.A. Hanania P. Darken D. Horstman et. al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the discus inhaler for the treatment of COPD Chest 124 2003 834-843
27. 2-agonists and corticosteroids in stable COPD Chest 126 2004 220-237
28. P.M. Van Grunsven C.P. van Schayck J.P. Derenne et. al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis Thorax 54 1999 7-14
29. J. Vestbo T. Sorensen P. Lange A. Brix P. Torre K. Viskum Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial Lancet 353 1999 1819-1823
30. R.A. Pauwels C.G. Lofdahl L.A. Laitinen et. al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948-1953
31. E.R. Sutherland H. Allmers N.T. Ayas A.J. Venn R.J. Martin Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis Thorax 58 2003 937-941
32. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
33. J.B. Soriano J. Vestbo N.B. Pride V. Kiri C. Maden W.C. Maier Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Eur Respir J 20 2002 1-7
34. S. Suissa Effectiveness of inhaled corticosteroids in COPD: Immortal time bias in observational studies Am J Respir Crit Care Med 168 2003 49-53
35. V.S. Fan C.L. Bryson J.R. Curtis et. al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization Am J Respir Crit Care Med 168 2003 1488-1494
36. S. Suissa Inhaled steroids and mortality in COPD: Bias from unaccounted immortal time Eur Respir J 23 2004 391-395
37. L.D. Fisher D.Y. Lin Time-dependent covariates in the Cox proportional-hazards regression model Annu Rev Public Health 20 1999 145-157
38. J.J. Hospers D.S. Postma B. Rijcken S.T. Weiss J.P. Schouten Histamine airway hyper-responsiveness and mortality form chronic obstructive pulmonary disease: A cohort study Lancet 356 2000 1313-1317
39. J. Vestbo E.F. Hansen Airway hyperresponsiveness and COPD mortality Thorax 56 Suppl 2 2001 ii11-ii14
40. R.A. Deyo D.C. Cherkin M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613-619
41. D. Collett Modelling survival data in medical research 2nd ed. 2003 Chapman & Hall/CRC Press Boca Raton, FL
42. P.D. Allison Survival analysis using the SAS® system: A practical guide 1995 SAS Institute Inc. Cary, NC
43. D.P. Tashkin M.D. Altose J.E. Connett R.E. Kanner W.W. Lee R.A. Wise Methacholine reactivity predicts changes with early chronic obstructive pulmonary disease. The Lung Health Study Research Group Am J Respir Crit Care Med 153 1996 1802-1811
44. B. Rijcken S.T. Weiss Longitudinal analyses of airway responsiveness and pulmonary function decline Am J Respir Crit Care Med 154 1996 S246-S249
45. J.W. Singer J.B. Willett Applied longitudinal data analysis: Modeling change and event occurrence 2003 Oxford University Press New York
46. K. Benson A.J. Hartz A comparison of observational studies and randomized, controlled trials N Engl J Med 342 2000 1878-1886
47. J. Concato N. Shah R.I. Horwitz Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 2000 1887-1892
48. D.D. Sin S.F. Man Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: Does the dose matter? Eur Respir J 21 2003 260-266
49. D.D. Sin S.F. Man J.V. Tu Inhaled glucocorticoids in COPD: Immortal time bias Am J Respir Crit Care Med 168 2003 126-127
50. V.A. Kiri N.B. Pride J.B. Sorian J. Vestbo Inhaled corticosteroids in COPD: Results from two observational designs free of immortal time bias Am J Respir Crit Care Med 172 2005 460-464
51. J.M. Samet Inhaled Corticosteroids and chronic obstructive pulmonary disease: New and improved evidence? Am J Respir Crit Care Med 172 2005 407-408
52. A.F. Connors Jr N.V. Dawson C. Thomas et. al. Outcomes following acute exacerbation of severe chronic obstructive lung disease: The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments) [published erratum appears in Am J Respir Crit Care Med 1997;155:386] Am J Respir Crit Care Med 154 1996 959-967
53. T.A.R. Seemungal G.C. Donaldson A. Bhowmik D.J. Jeffries J.A. Wedzicha Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 1608-1613
54. 1 decline in current smokers but not ex-smokers with mild chronic obstructive lung disease: Results from the lung health study Am J Respir Crit Care Med 164 2001 358-364
55. I.M. Osman D.J. Godden J.A. Friend et. al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease Thorax 52 1997 67-71
56. G.A. Traver Measures of symptoms and life quality to predict emergent use of institutional health care resources in chronic obstructive airways disease Heart Lung 17 1988 689-697
57. T.A. Seemungal G.C. Donaldson E.A. Paul et. al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418-1422
58. V.S. Fan J.R. Curtis T. Shin-Ping M.B. McDonell S.D. Fihn Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases Chest 122 2002 429-436
59. K. Amin D. Ludviksdottir C. Janson O. Nettelbladt et. al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma Am J Respir Crit Care Med 162 2000 2295-2301
60. A. Pesci G.A. Rossi G. Bertorelli A. Aufiero P. Zanon D. Olivieri Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis Am J Respir Crit Care Med 149 1994 1311-1316
61. D.E. Niewoehner M.L. Erbland R.H. Deupree et. al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease N Engl J Med 340 1999 1941-1947
62. T. Seemungal R. Harper-Owen A. Bhowmik et. al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 1618-1623
63. S. Sethi N. Evans B.J.B. Grant T.F. Murphy New strains of bacteria and exacerbations of chronic obstructive pulmonary disease N Engl J Med 347 2002 465-471
64. S. Sethi K. Muscarella N. Evans K.L. Klingman B.J.B. Grant T.F. Murphy Airway inflammation and etiology of acute exacerbations of chronic bronchitis Chest 118 2000 1557-1565